<DOC>
	<DOCNO>NCT01711749</DOCNO>
	<brief_summary>This open-label , randomize , two treatment , two sequence , two period crossover study , use crossover 2x2 design , subject randomly assign reference test formulation , order evaluate formulation bioequivalent .</brief_summary>
	<brief_title>Rosuvastatin Calcium Bioequivalence Study - Fast</brief_title>
	<detailed_description>The objective study confirm two formulation rosuvastatin calcium 20 mg tablet bioequivalent . Test formulation rosuvastatin calcium 20 mg tablet - manufacture Laboratorios Phoenix S.A.I.C.F/Argentina GlaxoSmithKline Brazil Ltda. , administration one single-dose tablet . Reference formulation rosuvastatin calcium 20 mg tablet ( Crestor® 20 mg - AstraZeneca Brasil Ltda . ) , administration one single-dose tablet . Sixty-four healthy volunteer , gender , age range 18 50 year old , receive test reference formulation fast condition , accord randomization list . In period , administration medication , blood sample collect follow time : 0:00 ( prior administration ) , 0:30 , 1:00 , 1:30 , 2:00 , 2:20 , 2:40 : 3:00 , 3:20 , 3:40 , 4:00 , 4:20 , 4:40 , 5:00 , 5:30 , 6:00 , 7:00 , 8:00 , 10:00 , 12:00 , 24:00 , 36:00 , 48:00 72:00 hour . The comparative bioavailability formulation evaluate base relevant pharmacokinetic parameter statistical comparison . Such parameter obtain directly determination drug active principle plasmatic concentration , base application non-compartmental pattern evaluation concentration drug oral administration .</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Man woman age 18 50 year . Women pregnant breastfeeding , man woman commit use efficient contraceptive method along entire study period ; Volunteers Asian descent , due difference pharmacokinetics rosuvastatin group people ; Volunteers cholecystectomy ; Female subject childbearing potential must become pregnant study period , thus , sexually inactive abstinence use contraceptive method failure rate &lt; 1 % . Inactivity sexual abstinence consistent usual lifestyle subject . Periodic abstinence withdrawal acceptable method contraception . Will accept method contraception failure rate le 1 % : oral contraceptive , either combined progestogen alone , injectable progesterone , implant levonorgestrel , estrogenic vaginal ring , Percutaneous contraceptive patch , intrauterine device ( IUD ) intrauterine system ( IUS ) meet failure rate &lt; 1 % , double barrier method , partner sterilization ( vasectomy documentation azoospermia ) prior female subject 's entry study , male sole partner subject ; Body mass index ≥ 18.5 ≤ 29.9 kg/m² ; Volunteers good health condition without significant disease medical criterion , per Clinical History ; Blood pressure , pulse temperature take , Physical examination , ECG complementary Lab examination ; The volunteer healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . A subject clinical abnormality laboratory parameter outside reference range population study may include Investigator Medical Monitor agree find unlikely introduce additional risk factor interfere study ; The volunteer must able understand nature purpose study , include risk adverse effect must show good intention cooperate researcher act accord requirement entire trial , confirm signature Informed Consent . The volunteer know hypersensitivity drug study chemically related compound ; History existence hepatic GI disease condition could interfere absorption , distribution , excretion metabolism drug ; Use maintenance therapy drug oral contraceptive ; History hepatic , renal , pulmonary , GI , neurological , hematological , psychiatric , cardiologic allergic problem etiology need drug treatment researcher considers clinically relevant ; Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) ; ECG finding , recommend researcher 's criterion participate study ; Results complementary lab test value consider normal , accord protocol guideline , unless researcher considers nonclinically significant ; Smoke abuse ; Daily ingestion five cup coffee ; History alcohol drug abuse ; Use regular medication along two week precede study commencement , use medication one week study commencement ; Hospitalization reason 8 week first period study ; Treatment along three month treatment commencement study drug know welldefined toxic potential major organ ; Participation pharmacokinetics study collection 300 mL blood ingestion experimental drug along six month treatment commencement study ; Donation loss ≥ 450 mL blood along three month precede study donation 1500 mL along 12 month treatment commencement study ; Positive result βHCG urine female volunteer ; A positive prestudy Hepatitis B surface antigen positive Hepatites C antibody result within 3 month o screen ; Female subject use contraceptive method meet failure rate &lt; 1 % ; Any condition prevents participation study , accord researcher 's judgment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>